DongKook Pharmaceutical Stock | Analysis for April 2026, Price & Rating

DongKook Pharmaceuti...

KOSDAQ:A086450

₩ 24.650,00

₩-300,00 (-1,20%)

24.650,00 ₩

₩-300,00 (-1,20%)

End-of-day quote: 04/23/2026

DongKook Pharmaceutical Stock Value

The analyst rating for KOSDAQ:A086450 is currently Buy.

Buy

DongKook Pharmaceutical Company Info

EPS Growth 5Y

1,67%

Market Cap

₩1.125,51 B

Long-Term Debt

₩22,90 B

Annual earnings

N/A

Dividend

₩197,20

Dividend Yield

0,80%

Founded

1968

Industry

Health Care

Country

South Korea

Website

DongKook Pharmaceutical

ISIN Number

KR7086450004

Website

http://www.dkpharm.co.kr

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

₩45.000,00

82.56%

Last Update: 04/23/2026

Analysts: 1

Highest Price Target ₩45.000,00

Average Price Target ₩45.000,00

Lowest Price Target ₩45.000,00

In the last five quarters, DongKook Pharmaceutical’s Price Target has risen from ₩11.755,69 to ₩23.000,00 - a 95,65% increase. One analysts predict that DongKook Pharmaceutical’s share price will increase in the coming year, reaching ₩45.000,00. This would represent an increase of 82,56%.

Top growth stocks in the health care sector (5Y.)

What does DongKook Pharmaceutical do?

DongKook Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products, including both prescription and over-the-counter medications. The company focuses on providing high-quality healthcare solutions to improve patient outcomes and enhance the quality of life through innovative medicine. Its commitment to research and development, along with a diverse product portfolio, positions the company as a vital contributor to the h...

Business Segments

The company operates through several key segments, each dedicated to different aspects of the pharmaceutical market. The primary segments include prescription medications, over-the-counter products, health supplements, and healthcare services.

Prescription Pharmaceuticals: This segment represents the core of the company’s operations, focusing on innovative drug development and offering a range of specialized medicines targeting various therapeutic areas, including oncology and neurology. The company invests heavily in R&D to ensure the continuous introduction of new and improved formulations to meet the evolving needs of healthcare providers and patients.

Over-the-Counter (OTC) Products: The OTC segment is vital for promoting general health and wellness. The company offers various non-prescription products designed to treat common ailments, such as pain relief, cold treatments, and digestive aids. This segment is characterized by robust marketing strategies and partnerships with retail and pharmacy chains to maximize product visibility and accessibility to consumers.

Health Supplements: Recognizing the growing demand for preventive healthcare, the health supplements division provides dietary supplements aimed at improving overall health and wellness. This segment leverages natural ingredients and focuses on developing products that appeal to health-conscious consumers.

Healthcare Services: In addition to product development, The company is expanding its scope into healthcare services, providing consultancy and support to healthcare professionals. This segment enhances the company's integration into the healthcare system and establishes strong relationships with its client base.

Business Strategy

The company’s business strategy revolves around innovation, quality, and customer-centricity. The company aims to strengthen its position in the pharmaceutical market through a multi-faceted approach that emphasizes research and development, strategic partnerships, and market expansion.

The focus on R&D is paramount for the company, as it seeks to develop new and enhanced formulations that address unmet medical needs. By investing in cutting-edge technology and collaborating with academic institutions and research organizations, the company aims to accelerate the development of breakthrough therapies.

Products and Services

The product portfolio of the company is diverse, encompassing various categories essential for healthcare solutions.

Prescription Drugs: This includes a range of innovative medications catering to chronic diseases, acute health conditions, and specialty therapeutic areas. The company’s prescription products focus on improving treatment outcomes and enhancing patient compliance with medications.

OTC Products: The company manufactures a variety of non-prescription medications designed for managing common health issues. This range includes analgesics, digestive aids, cough and cold remedies, and vitamin supplements, aimed at providing immediate relief to consumers.

Health Supplements: The health supplements division offers products aimed at fortifying well-being. This includes vitamins, minerals, herbal extracts, and functional foods that support various health needs, from immune support to mineral replenishment.

Healthcare Services: Beyond products, the company provides value-added services aimed at improving the understanding and usage of its medications. This includes healthcare consultancy, educational resources for healthcare professionals, and patient support programs designed to empower patients in managing their health.

Geographical Markets Served

The company operates in both domestic and international markets, expanding its footprint to meet the needs of diverse populations. The company’s extensive distribution network spans across multiple regions, facilitating access to its products in pharmacies, hospitals, and healthcare facilities.

The strategic focus on international markets is evident as the company aims to penetrate emerging markets, Drive demand for its innovative pharmaceuticals, particularly in Asia and Latin America. By adapting its product offerings to meet local regulations and consumer preferences, The company is poised for sustained growth.

Seasonality

The seasonal trends in the pharmaceutical industry can significantly affect sales. The company observes increased demand for specific products during certain times of the year, such as allergy medications in the spring or cold and flu remedies during the winter months. Understanding and anticipating these seasonal fluctuations allows the company to optimize inventory management and marketing strategies.

Customers

The company serves a diverse range of customers, including healthcare professionals, hospitals, pharmacies, and consumers in the retail market. The company maintains a robust customer base across different segments by offering quality products and comprehensive support services. The increasing engagement with healthcare providers enables the company to gather valuable feedback, which informs product improvement and development strategies.

Sales and Marketing

The marketing and distribution strategy of the company includes a combination of direct sales, partnerships with distributors, and online platforms. The company utilizes targeted marketing campaigns to reach specific customer segments effectively. By leveraging digital marketing channels, the company enhances its outreach and engages consumers directly, creating awareness about new products and health initiatives.

History

The company was founded in 1968. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in 1982.

DongKook Pharmaceutical Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** approximately 60% of revenue **Cosmetic Products:** approximately 25% of revenue **Health Products:** approximately 15% of revenue **TOP 3 Markets:** 1. **South Korea:** approximately 50% 2. **China:** approximately 20% 3. **Japan:** approximately 15% Don...

At which locations are the company’s products manufactured?

**Production Sites:** Headquarters in Seoul, South Korea; Production facilities in Hwaseong and Cheonan. DongKook Pharmaceutical Co., Ltd. mainly produces its products in South Korea. The company's headquarters is located in Seoul, while the main production facilities are situated in Hwaseong...

What strategy does DongKook Pharmaceutical pursue for future growth?

**Revenue Growth:** Estimated 8-10% annually (based on historical data and market trends until 2023) **Research & Development:** Investments of approximately 15% of revenue in R&D (latest available data) DongKook Pharmaceutical Co., Ltd. pursues a growth strategy that is heavily focused on...

Which raw materials are imported and from which countries?

**Main raw materials:** Pharmaceutical active ingredients, excipients, packaging materials **Countries of origin:** China, India, Germany, USA DongKook Pharmaceutical Co., Ltd. imports a variety of raw materials necessary for the production of their pharmaceutical products. These include pharmace...

How strong is the company’s competitive advantage?

**Market Share:** Estimated 12% in the South Korean pharmaceutical market (2025) **R&D Expenses:** 8% of revenue (2025) **Product Innovations:** 3 new product launches (2025) DongKook Pharmaceutical Co., Ltd. has a significant competitive advantage in the South Korean pharmaceutical market,...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated 35% (2026) **Insider Buys/Sells:** No significant changes in the last year (2025) The institutional investor share in DongKook Pharmaceutical Co., Ltd. is estimated at 35%. This indicates a moderate interest from institutional investors in the company, s...

What percentage market share does DongKook Pharmaceutical have?

**Market share of DongKook Pharmaceutical Co., Ltd.:** Estimated 3-5% (2026) **Major competitors and their estimated market shares:** 1. **Samsung Biologics Co., Ltd.:** 15-20% 2. **Celltrion Inc.:** 12-15% 3. **Hanmi Pharmaceutical Co., Ltd.:** 8-10% 4. **Yuhan Corporation:** 7-9% 5. **Green Cross...

Is DongKook Pharmaceutical stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **Research and Development Ratio:** 12% of revenue (2025) **Market Share in the Asian Region:** 5% (2025) DongKook Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025, indicating a solid business performance. The company is heavily investing in researc...

Does DongKook Pharmaceutical pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2025) **Dividend History:** Continuous payout since 2018 DongKook Pharmaceutical Co., Ltd. regularly pays dividends to its shareholders. The dividend yield was approximately 2.5% in 2025, which can be considered stable compared to other companies in the industry. The...

New support ticket

Explore

DongKook Pharmaceutical Stock Value

DongKook Pharmaceutical Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does DongKook Pharmaceutical do?

DongKook Pharmaceutical Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

DongKook Pharmaceutical Stock Value

DongKook Pharmaceutical Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does DongKook Pharmaceutical do?

DongKook Pharmaceutical Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.